Status:
UNKNOWN
The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19)
Lead Sponsor:
King Abdullah International Medical Research Center
Conditions:
Moderate Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
There is an urgent need to explore therapeutic options for SARS-CoV-2 in order to face the pandemic. The selected intervention was based on that zafirlukast will have dual effect; first it will block ...
Eligibility Criteria
Inclusion
- Age of 18 years or above
- Diagnosed with COVID-19 by PCR confirmed SARS-coV-2 viral infection.
- Able to sign the consent form and agree to clinical samples collection
- Moderate symptomatic COVID-19 patients, (any or all of the followings: fever or cough or SOB)
- Admitted to the hospital (outside the ICU)
- Patients had to be enrolled within 10 days of symptoms onset.
- willingness to comply with all study procedures and availability for the duration of the study
Exclusion
- Asthmatic patient using antiasthma medications
- Being in the hospital or in home isolation for more than 72 hours before the start of the study drug.
- Known sensitivity/allergy to the study drug
- Pregnancy
- Patient refused
- Chronic liver disease
- Severe mental disorder
- Unstable patients requiring ICU admission
- Participating in other clinical trial
Key Trial Info
Start Date :
February 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04871828
Start Date
February 28 2021
End Date
December 1 2021
Last Update
May 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Abdulaziz Medical city, MNGHA
Riyadh, Saudi Arabia, 11426